Catalyst Story

<div class='circular--portrait' style='background:#006400;color: #FFE4E1;font-size:4em;'>CB</div>
CBIO -- USA Stock  

USD 6.19  0.48  8.41%

While some of us are excited about healthcare space, it makes sense to outline Catalyst Biosciences in greater detail to make a better perception of its potential. As we have suggested previously, Catalyst Biosciences is beginning its slide as institutional investors shift to be more bearish due to the increased sector volatility. Catalyst Biosciences follows the market closely. The returns on the market and returns on Catalyst Biosciences appear somewhat sensitive to each other for the last few months. Persistent essential indicators of the company may entail signs of short-term price drift for institutional investors. Catalyst Biosciences is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 5th of November 2020.
Published over a month ago
View all stories for Catalyst Biosciences | View All Stories
Should you acquire Catalyst Biosciences (NASDAQ:CBIO) based on latest technical indicators?
The entity's average rating is Buy from 2 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Catalyst Biosciences market sentiment investors' perception of the future value of Catalyst. Let us look at a few aspects of Catalyst technical analysis.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Catalyst Biosciences. In general, we focus on analyzing Catalyst Biosciences stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Catalyst Biosciences's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Catalyst Biosciences's intrinsic value. In addition to deriving basic predictive indicators for Catalyst Biosciences, we also check how macroeconomic factors affect Catalyst Biosciences price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.

How does Catalyst Stands against Peers?

Analyzing Catalyst Biosciences competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Catalyst Biosciences across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Catalyst Biosciences Competition Details

How Catalyst utilizes its cash?

To perform a cash flow analysis of Catalyst Biosciences, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Catalyst Biosciences is receiving and how much cash it distributes out in a given period. The Catalyst Biosciences cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Catalyst Biosciences Net Cash Flow from Operations is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Operations is estimated at (44.76 Million)

Acquisition by Ling Geoffrey Md of 2616 shares of Catalyst Biosciences subject to Rule 16b-3

Legal trades by Catalyst Biosciences insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Catalyst insider trading alert for grant of common stock by Ling Geoffrey Md, the corporate stakeholder, on 2nd of October 2020. This event was filed by Catalyst Biosciences Inc with SEC on 2020-10-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Closer look at Catalyst Biosciences Variance

Catalyst Biosciences has current Variance of 17.83. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
17.83
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Catalyst Biosciences Variance to its closest peers:
CBIO
EARS
DYAI
EDIT
EQ
CBIO17.827155950293903
EARS36.12
DYAI9.71
EDIT19.19
EQ29.02

High level of complacency for Catalyst Biosciences after the latest price slide

Latest semi deviation is at 4.14. Catalyst Biosciences exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Catalyst Biosciences individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Catalyst Biosciences future systematic risk.

Our Conclusion on Catalyst Biosciences

Whereas many of the other players within the biotechnology industry are still a little expensive, even after the recent corrections, Catalyst Biosciences may offer a potential longer-term growth to institutional investors. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither buy new shares of Catalyst nor sell your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catalyst Biosciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Catalyst Biosciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com